Toujeo gets FDA approval

Sanofi's new Toujeo diabetes drug, the once daily, long-acting basal insulin to treat type 1 and type 2 diabetes won U.S. regulatory approval. Toujeo is a more potent follow-up to top-selling Lantus. Sanofi is hoping to convert patients to Toujeo as Lantus is due to lose its U.S. patent protection this month.

6th World Congress of DiabetesIndia: April 9-12 2015, Chennai, Tamil Nadu

Dear Friends,
In 3 weeks, Chennai city in South India will host the 6th World Congress of DiabetesIndia from 9-12 April, 2015 at Hotel ITC Grand Chola Convention Centre, Chennai.

The World Congress of DiabetesIndia at Chennai will be a truly unique international convention blessed with the presence of International Presidents of Scientific organisations such as President Elect of IDF, Dr. Shaukat Sadikot who is also the President of DiabetesIndia, Presidents of ADA, EASD, ISPAD, immediate past President of International Atherosclerotic Society, Presidents of API, RSSDI, Endocrine Society and Indian Obesity Society.

The scientific program is richly packed with 35 oral presentations, more than 100 posters, 200 lectures, 12 debates, more than 10 case presentations, 10 plenary sessions by international speakers, 5 keynote speakers, 6 workshops and for the first time workshop on medical paper writing and grant writing.

We promise all delegates informative learning and a cherishing experience at the 6th World Congress of DiabetesIndia!. We cordially invite physicians, researchers, students, dieticians and diabetes educators to be part of this unique scientific feast spread across 4 days. Visit: www.diabetesindia2015.com